Dare Bioscience

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Daré Bioscience reports Q1 progress in women's health innovation

Daré Bioscience showcased progress in Q1 2024 with achievements in product commercialization and pipeline advancements, despite a reported comprehensive loss.
The company's focus on women's health innovation and commitment to driving value for stakeholders position them well for future growth.
While facing financial challenges and competitive pressures, Daré Bioscience has opportunities to capitalize on its strong pipeline and attract investor interest.
Continued momentum in Phase III studies and technology development present avenues for growth and market expansion in the women's health sector.

Dare Bioscience reports strong Q2 earnings, advances women's health therapies

Dare Bioscience delivered a robust Q2 2024 performance marked by cost efficiencies, revenue generation from strategic transactions, and progress in key product developments.
The company's focus on women's health and commitment to advancing therapies position it well for future growth and market leadership in a segment with significant unmet needs.
While facing challenges in market adoption and regulatory interactions, Dare Bioscience has opportunities to drive revenue growth, expand its market presence, and diversify its product portfolio.
Overall, Dare Bioscience's Q2 earnings call reflects a company on a positive trajectory, with a strong financial foundation and a strategic focus on advancing innovative solutions for women's health.

Daré Bioscience reports cost reductions and promising pipeline developments

Daré Bioscience showcased strong financial discipline with notable expense reductions and strategic funding acquisitions, positioning the company for sustainable growth.
Progress in late-stage candidates and FDA interactions signals promising developments in the pipeline, underscoring Daré's commitment to innovation in women's health.
While facing financial challenges and operational hurdles, Daré's focus on disruptive products and leveraging funding opportunities presents avenues for future success.
Overall, Daré Bioscience's Q3 performance reflects a balance of cost management, innovation, and strategic positioning in the healthcare market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newborns Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newborns

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

$5 million at closing and up to $7 million of additional committed funding $5 million at closing and up to $7 million of additional committed funding

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Officer Lisa Walters-Hoffert - CFO Conference Call Participants Catherine Novack - Jones Trading Doug Tsao - H.C. Wainright Operator Welcome to the conference hosted by Daré Bioscience to Review the Company's Third Quarter Financial Results and to provide a General Business Update.

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agreement with Organon Ovaprene®: commencement of pivotal Phase 3 contraceptive efficacy study Sildenafil Cream, 3.6%: end-of-Phase 2 meeting with FDA DARE-PDM1: Phase 1 clinical study topline data SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will participate in the following conferences in November 2023:

Daré Bioscience to Participate in Three November Conferences

Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it has entered into a definitive agreement with an institutional investor and an investor affiliated with the licensor of one of the company's early stage product candidates for the purchase and sale of 10,000,000 shares of the company's common stock and warrants to purchase up to 10,000,000 shares of the company's common stock in a registered direct offering priced at-the-market under Nasdaq rules. Each warrant is exercisable for one share of the company's common stock. The offering price was $0.70 per share of common stock and accompanying warrant. The warrants will be exercisable beginning six months after issuance, have a term of five and one-half years from the date of issuance and have an exercise price of $0.77 per share. The closing of the offering is expected to occur on or about September 1, 2023, subject to the satisfaction of customary closing conditions.

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago.

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial Sale Ovaprene® (hormone-free monthly contraception) – Pivotal Phase 3 Contraceptive Efficacy Study – Patient Enrollment to Begin 4Q2023 Sildenafil Cream, 3.6% (female sexual arousal disorder and female sexual interest/arousal disorder) - preparations for end-of-Phase 2 meeting with FDA DARE-PDM1 (primary dysmenorrhea) – Phase 1 Clinical Study Topline Data Menopause programs: IND related activities for DARE-HRT1 (vasomotor symptoms of menopause) and DARE-VVA1 (vulvovaginal atrophy, a common condition in postmenopausal women, including those whose menopause resulted from receiving certain breast cancer treatments); Phase 3 and Phase 2 clinical study initiation plans, respectively SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended June 30, 2023, and provided a company update.

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the publication of positive preliminary efficacy results from its Phase 1/2 clinical study of DARE-HRT1 in healthy postmenopausal women. DARE-HRT1, an investigational ethylene vinyl acetate copolymer intravaginal ring (IVR) designed to release bio-identical 17β2-estradiol and progesterone over 28 days as part of a hormone therapy regimen, is part of Daré's proprietary IVR technology platform originally developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School. DARE-HRT1 is being developed for the treatment of moderate-to-severe VMS due to menopause in women with intact uteri.

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter ended June 30, 2023 and to provide a Company update.

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The women's health-focused biopharmaceutical company on Tuesday reported positive results from its Phase 2b RESPOND study evaluating its proprietary topical formulation of sildenafil (sildenafil cream 3.6%) as a treatment for female sexual arousal disorder (FSAD), a condition for which there is no Food and Drug Administration (FDA)-approved treatment.

Daré Bioscience's 'female Viagra' could be first-in-category product: broker

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the 9th Annual International Symposium of Drug Delivery Systems being held July 12-14, 2023, in Amsterdam, the Netherlands.

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO, will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, being held June 20 – 22, 2023.

Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary, investigational formulation of tamoxifen for intravaginal administration to treat vulvovaginal atrophy (VVA) in women without the use of hormones. The journal article, “Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy,” was published online and will appear in Climacteric, the official journal of the International Menopause Society. The randomized, double-blind, placebo-controlled study was designed to evaluate the pharmacokinetics, safety and pharmacodynamics of DARE-VVA1 in postmenopausal participants with moderate to severe VVA.

Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Commercial Officer Lisa Walters-Hoffert – Chief Financial Officer Conference Call Participants Catherine Novack – Jones Research Kumar Raja – ROTH Capital Kemp Dolliver – Brookline Capital Markets Doug Tsao – H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended March 31, 2023, and to provide a General Business Update.

Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago.

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline Data XACIATO™ First Commercial Sale Ovaprene Pivotal Contraceptive Efficacy Study Initiation DARE-PDM1 Phase 1 Clinical Study Topline Data Activities to support IND Submission and Clinical Study Initiation for DARE-VVA1 (Phase 2) and DARE-HRT1 (Phase 3) SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update.

Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for the quarter ended March 31, 2023 and to provide a Company update.

Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023

Dare Bioscience, Inc. (NASDAQ:DARE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Sabrina Johnson - President & Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Conference Call Participants Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright Kumaraguru Raja - ROTH Capital Joanne Lee - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company's Financial Results for the Year Ended December 31, 2022 and to provide a general business update.

Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript

Conference Call and Webcast Today at 4:30 p.m. ET

News for Dare Bioscience Stock (DARE)